VRTX Q1 2025 Earnings — Vertex Pharmaceuticals Incorporated Revenue & Financial Results | Market Cap Arena

VRTXVertex Pharmaceuticals Incorporated

$129B

Q1 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2.8B+3.1% YoY

Gross Profit

$2.4B86.9% margin

Operating Income

$630M22.7% margin

Net Income

$646M23.3% margin

EPS (Diluted)

$2.49

QoQ Revenue Growth

-4.9%

Cash Flow

Operating Cash Flow

$819M

Free Cash Flow

$778M

Stock-Based Comp.

$166M

Balance Sheet

Total Assets

$22.9B

Total Liabilities

$6.4B

Stockholders' Equity

$16.5B

Cash & Equivalents

$4.7B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2.8B	$2.7B	+3.1%
Gross Profit	$2.4B	$2.3B	+2.7%
Operating Income	$630M	$1.1B	-44.7%
Net Income	$646M	$1.1B	-41.2%

Revenue Segments

TRIKAFTA/KAFTRIO

$2.5B92%

Manufactured Product, Other

$171M6%

ALYFTREK

$54M2%

Geographic Segments

UNITED STATES

$1.7B60%

Europe

$827M30%

Other, Non U.S.

$280M10%